The risk of hematopoietic growth factor therapy in newborn infants

被引：3

作者：

Zipursky, A ^{[1
]}

机构：

[1] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada

来源：

关键词：

D O I：

10.1203/00006450-200205000-00001

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

[No abstract available]

引用

页码：549 / 549

页数：1

共 7 条

[1] Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.
Casadevall, N
Nataf, J
Viron, B
Kolta, A
Kiladjian, J
Martin-Dupont, P
Michaud, P
Papo, T
Ugo, V
Teyssandier, I
Varet, B
Mayeux, P
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (07) : 469 - 475
[2] LaricchiaRobbio L, 1997, J CELL PHYSIOL, V173, P219, DOI 10.1002/(SICI)1097-4652(199711)173:2<219::AID-JCP25>3.0.CO
[3] 2-9
[4] Thrombocytopenia caused by the development of antibodies to thrombopoietin
Li, JZ
Yang, C
Xia, YP
Bertino, A
Glaspy, J
Roberts, M
Kuter, DJ
[J]. BLOOD, 2001, 98 (12) : 3241 - 3248
[5] INDUCTION OF ANTI-RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (ESCHERICHIA COLI-DERIVED) ANTIBODIES AND CLINICAL EFFECTS IN NONIMMUNOCOMPROMISED PATIENTS
RAGNHAMMAR, P
FRIESEN, HJ
FRODIN, JE
LEFVERT, AK
HASSAN, M
OSTERBORG, A
MELLSTEDT, H
[J]. BLOOD, 1994, 84 (12) : 4078 - 4087
[6] SOLA MC, J PEDIAT HEMATOL ONC, V23, P179
[7] Erythropoietin therapy for premature infants: Cost without benefit?
Zipursky, A
[J]. PEDIATRIC RESEARCH, 2000, 48 (02) : 136 - 136